Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.Explore and learn more about Conference Series : World's leading Event Organizer
Robust immunity
Many attempts have focused on the use of either immunomodulators or antigen delivery systems to obtain an efficacious vaccine. Here, we report a novel approach that combined an immunomodulator and delivery system to enhance antigen association and induce robust immunity. We expressed a recombinant lipidated dengue-1 envelope protein domain III (LD1ED III) and its non-lipidated form, D1ED III, in an Escherichia colisystem. The LD1ED III contains a bacterial lipid moiety, which is a potent immunomodulator. We demonstrated that LD1ED III possesses an inherent immunostimulation ability that can activate RAW 264.7 macrophage cells by up-regulating their expression of CD40, CD80, CD83, CD86 and MHC II, whereas D1ED III could not induce the up-regulation of these molecules. Moreover, combining LD1ED III with a multiphase emulsion system (called PELC) increased the antigen association more than either combining D1ED III with PELC or the antigen alone. Enhanced antigen association has been shown to correlate with stronger T cell responses, greater antibody avidity and improved neutralizing capacity. Our results demonstrate that combining recombinant lipoproteins with PELC improved both the intensity and the quality of the immune response. This approach is a promising strategy for the development of subunit vaccines that induce robust immunity
OMICS International Organizes 1000+ Global Events. Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Accesswhich contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The Conference serieswebsite will provide you list and details about the conference organize worldwide.
Scope & Importance
Global revenue for vaccine technologies was nearly $31.8 billion in 2011. This market is expected to increase from $33.6 billion in 2012 to $43.4 billion in 2017 at a compound annual growth rate (CAGR) of 5.3%.An overview of the global market for human and animal (veterinary) vaccines and related vaccine technologies. Analyses of global market trends, with data from 2010, 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017. Examination of current and future strategies within the human and animal (veterinary) vaccines markets, including attenuated (live) vaccines, inactivated (killed) vaccines, conjugate vaccines, recombinant/recombinant DNA (rDNA) vaccines, subunit vaccines, toxoid vaccines, and combination vaccines. A breakdown of the seven major categories of vaccines broken down by market shares belonging to leading manufacturers and/or suppliers. Discussion of human and animal (veterinary) vaccines as to their prophylactic or therapeutic use, with emphasis in the meningococcal/pneumococcal vaccines, influenza vaccines, pediatric vaccines, adult/adolescent vaccines, and travel vaccines.
: Conferences from OMICS International: :
Protein Engineering Conference October 26-28, 2015 Chicago, USA
Vaccines Middle East Conference September 28-30, 2015 Dubai, UAE
Vaccines Asia Pacific Conference November 10-12, 2016 Melbourne, Australia
Vaccines 2015 November 30-December 02, 2015 San Francisco, USA
Euro Vaccines Conference June 16-18, 2016 Rome, Italy
Hepatities Vaccines Conference June 16-18, 2016 Rome, Italy
Hiv Vaccines Conference Oct 3-5, 2016 Miami, USA
Vaccines USA Conference November 30-December 02, 2015 San Francisco, USA
Proteomics Conference September 01-03, 2015 Valencia, Spain
World Proteomics Conference March 29-30, 2016 Atlanta, USA
Conferences out of OMICS:
2015 IMMUNIZATION SUMMIT! NAMPA, IDAHO MONDAY, SEPTEMBER 21, 2015
14th Annual Measles and Rubella Initiative Meeting: Focusing on the Human and Financial Costs of Measles Washington, USA September 15-16, 2015
19th Annual Conference on Vaccine Research April 18-20, 2016 Baltimore, MD
Clinical Vaccinology Course Bethesda, MD November 13, 2015
9th Vaccine & ISV Congress 18-20 October 2015 | Lotte Hotel, Seoul, South Korea
2016 North Dakota State Immunization Conference August 3-4, 2016, Bismarck, ND
Relevant societies and associations:
Immunization Action Coalition
The International Society for Vaccines
Center for Knowledge Societies
Applied Research on Cancer (ARC-NET)
The network of National Cancer Institutions of Latin America (RINC)
American Cancer Society
African Organization for Research & Training in Cancer (AORTIC)
GAVI, THE VACCINE ALLIANCE
Centre of Genomics and Policy (CGP)
Companies:
Vaccine Delivery Innovation Initiative
Four Seasons Pharmacy
Dubai Health authority
pfizer
Sanofi
GlaxoSmithKline
Novartis
MSD
Antivenom & vaccine Production centre
The centre for food security &public Health
National Institute of Agrobiological SciencesGenebank
merck
This page will be updated regularly.
This page was last updated on April 19, 2024
